Raju Prasad - 14 Mar 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Financial Officer
Signature
/s/ AJ Silver, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
14 Mar 2024
Net transactions value
-$256,160
Form type
4
Filing time
18 Mar 2024, 17:45:14 UTC
Previous filing
17 Oct 2023
Next filing
22 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +10,000 10,000 14 Mar 2024 Direct F1
transaction CRSP Common Shares Sale $256,160 -3,524 -35% $72.69 6,476 15 Mar 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -10,000 -25% 30,000 14 Mar 2024 Common Shares 10,000 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3 This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027.